Dark

KALA
Kala Pharmaceuticals Inc
stock NASDAQ

At Close

5/30/2023 3:59:30 PM EDT

14.40USD-4.319%(-0.65)0

12.04Bid 15.61Ask 3.57Spread IEX

Pre-market

5/30/2023 9:25:30 AM EDT

15.05USD+0.004%(+0.00)0

After-hours

5/30/2023 4:20:30 PM EDT

14.55USD+1.042%(+0.15)0

Overview HistoricalMore

open chart

Market Cap

33.821M

CEO

Mark Iwicki

Headquarters

Watertown, Massachusetts, USA

Industry

Drug Manufacturers-Specialty & Generic

Next Earnings

2023-08-10 (72d)

Last Split

2022-10-211for50reverse

OMER XLV

KALA Stats

Avg. Vol. 10 Day

97,807

Avg. Vol. 30 Day

119,713

Employees

Market Cap

33,821,093

Shares Out.

2,348,687

Float

1,997,958

On/Off Exchange

43%/57%

6 Month Beta

1.52

1 Year Beta

0.85

2 Year Beta

0.92

3 Year Beta

0.84

52 Week Low

3.54

52 Week High

56.72

SMA50

16.07

SMA200

14.08

1 Week

-13.88%

1 Month

-6.25%

3 Month

+41.59%

6 Month

+172.21%

1 Year

-17.29%

2 Year

-94.71%

5 Year

-98.10%

Dec 17, 2021

04:01PM EST Kala Pharmaceuticals, Inc. (NASDAQ:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). GlobeNewswire Inc

Nov 24, 2021

03:03PM EST Kala Pharma 13D Filing From Mark Blumenkranz Shows Activist Stake On 7.4% In Co. Benzinga

Nov 18, 2021

04:01PM EST Kala Pharmaceuticals, Inc. (Nasdaq:KALA), today announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Companys 2017 Equity Incentive Plan in accordance with Nasdaq Listing Rule 5635(c)(4). GlobeNewswire Inc

Nov 15, 2021

11:11AM EST Kala Sees Submitting Investigational New Drug Application To FDA For KPI-012; Subject To Regulatory Clearance, Sees Initiating Phase 2/3 Trial For Persistent Corneal Epithelial Defect In Q3'22 Benzinga

11:10AM EST Kala Pharmaceuticals Q3 EPS $(0.43), Inline, Sales $3.10M Miss $5.16M Estimate Benzinga

More News

Profile

Kala is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative therapies for diseases of the eye. Kala has applied its AMPPLIFY® mucus-penetrating particle (MPP) Drug Delivery Technology to two ocular therapies, EYSUVIS™ (loteprednol etabonate ophthalmic suspension) 0.25% for the short-term (up to two weeks) treatment of signs and symptoms of dry eye disease and INVELTYS® (loteprednol etabonate ophthalmic suspension) 1% for the treatment of post-operative inflammation and pain following ocular surgery. The Company also has a pipeline of pre-clinical development programs targeted to address unmet medical needs, including both front and back of the eye diseases.

KALA Stock Summary

Kala Pharmaceuticals Inc (NASDAQ:KALA) stock price today is $14.40, and today's volume is 0. KALA is down -4.319% today. The 30 day average volume is 119,713. KALA market cap is 33.821M with 2,348,687 shares outstanding.